Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study

Lapadula, Giuseppe

DOI: https://doi.org/10.1007/s15010-024-02250-9

2024-04-24

Infection

Abstract:Purpose Antibodies against SARS-CoV-2 spike (anti-S) may confer protection against symptomatic COVID-19. Whether their level predicts progression among those with COVID-19 pneumonia remains unclear. Methods We conducted a retrospective cohort study to assess predictors of anti-S levels and whether anti-S titer is associated with death or mechanical ventilation (MV). Adults hospitalized for COVID-19 pneumonia between July 2021 and July 2022 were enrolled if anti-S had been measured within 72 h of admission. Predictors of anti-S level were explored using multivariable quantile regression. The association between anti-S levels and 30-day death/MV was investigated via multivariable logistic regression. Analyses were stratified by vaccine status. Results The median anti-S level was 1370 BAU/ml in 328 vaccinated and 15.5 BAU/ml in 206 unvaccinated individuals. Among the vaccinated, shorter symptom duration ( p = 0.001), hematological malignancies ( p = 0.002), and immunosuppressive therapy ( p = 0.004) were associated with lower anti-S levels. In the unvaccinated group, symptom duration was the only predictor of anti-S levels ( p < 0.001). After 30 days, 134 patients experienced death or MV. Among vaccinated individuals, higher anti-S levels correlated significantly with lower death/MV risk (per log 2 increase, OR 0.88, 95%CI 0.81–0.97), irrespective of age and solid malignancies. Among unvaccinated, a marginally protective effect was observed (OR 0.86, 95%CI 0.73–1.01), independent of age, immunosuppressive therapy, and diabetes. Adjustment for monoclonal antibody treatment strengthened the association (OR 0.81, 95%CI 0.68–0.96). Conclusion This study suggests that levels of anti-S antibodies can predict critical or fatal outcomes in COVID-19 pneumonia patients, regardless of vaccination. Whether anti-S Ab could guide risk assessment and vaccination boosting merits further evaluation.

infectious diseases

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether anti - spike protein antibody levels (anti - S antibody levels) can predict the risk of clinical progression in hospitalized patients with COVID - 19 pneumonia, especially the risk of death or the need for mechanical ventilation. Specifically, the study aims to evaluate which factors are associated with anti - spike protein antibody levels and whether these antibody levels can be used as predictive indicators to identify patients who may develop severe or fatal outcomes, regardless of their vaccination status.

### Research Background
- **Clinical manifestations of COVID - 19**: The clinical manifestations of COVID - 19 vary widely, ranging from asymptomatic to severe. Although the factors affecting disease progression have not been fully identified, studies have shown that a rapid and effective immune response to SARS - CoV - 2 can prevent severe clinical manifestations.
- **Role of anti - spike protein antibodies**: Anti - spike protein antibodies (anti - S antibodies) play a key role in the immune response and are considered potential prognostic markers.

### Research Objectives
- **Evaluate factors affecting anti - spike protein antibody levels**: Study which factors are associated with anti - spike protein antibody levels in hospitalized patients.
- **Evaluate the relationship between anti - spike protein antibody levels and clinical progression**: Explore whether anti - spike protein antibody levels can predict the risk of death or the need for mechanical ventilation within 30 days in hospitalized patients.

### Research Methods
- **Study design**: A retrospective cohort study, including patients hospitalized with COVID - 19 pneumonia from July 1, 2021 to July 31, 2022.
- **Inclusion criteria**: ≥18 years old, positive for SARS - CoV - 2 nucleic acid test at admission, having radiological or clinical evidence of COVID - 19 - related pneumonia, and anti - spike protein antibody levels measured within 72 hours of admission.
- **Statistical analysis**: Multivariate quantile regression and logistic regression analysis were used to evaluate the predictive factors of anti - spike protein antibody levels and their relationship with the risk of death or mechanical ventilation within 30 days.

### Main Findings
- **Predictive factors of anti - spike protein antibody levels**:
- **Vaccinated patients**: Shorter symptom duration, hematological malignancies, and immunosuppressive therapy were associated with lower anti - spike protein antibody levels.
- **Unvaccinated patients**: Symptom duration was the only significantly associated factor.
- **Relationship between anti - spike protein antibody levels and clinical progression**:
- **Vaccinated patients**: Higher anti - spike protein antibody levels were significantly associated with a lower risk of death or mechanical ventilation (for each additional log2 unit, OR 0.88, 95%CI 0.81 - 0.97).
- **Unvaccinated patients**: Higher anti - spike protein antibody levels had a marginal protective effect on the risk of death or mechanical ventilation (OR 0.86, 95%CI 0.73 - 1.01).

### Conclusions
- **Main conclusion**: Anti - spike protein antibody levels can predict the risk of developing severe or fatal outcomes in patients with COVID - 19 pneumonia, regardless of their vaccination status.
- **Future directions**: Further evaluate whether anti - spike protein antibody levels can be used to guide risk assessment and booster vaccination.

Through this study, the authors hope to provide a useful tool for clinicians to better identify and manage high - risk patients.